Sildenafil Citrate Tablet, Film Coated
Product Images NDC 51655-793

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 51655-793). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 793 20 Master Bottle Label Approval Rev A 01 22)

This is a description of Sildenafil tablets, USP with 20mg strength. The package contains 20 tablets to be stored within a specific temperature range. The dosage and other important information should be checked from the instructional insert. It is repackaged from a specific lot number by TruPharma LLC and repackaged by Northwind Pharmaceuticals from Indianapolis. The tablets contain Sildenafil citrate USP, which is equivalent to 20mg. The expiration date and lot number are also specified.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

This is a table showing the recommended nodose adjustment for various drugs interaction with Sildenafil. The table includes details of drugs such as Acitomycin®, Bosentan, Cimetidines, Evomyeint, Maslox®, OralContraceptives™, Rionavit, and Sapionis K8. The table provides information on how to adjust the dosages of these drugs concerning the administration of Sildenafil.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

This is a drug interaction chart that shows how acenocoumarol interacts with other drugs. The chart displays the recommended fold change and 90% CI for INR AUC, INR Cmax, BT, AUC, and Cmax when acenocoumarol is taken together with other drugs. The drugs shown include aspirin, atorvastatin, bosentan, doxazosin, ethinyloestradiol, levonorgestrel, phenprocoumon, ritonavir, saquinavir, and tolbutamide. The interaction of ritonavir on sildenafil PK is also mentioned. Sildenafil added to bosentan therapy does not show any benefit on exercise capacity.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

This appears to be a graph showing changes in meters over time in a study. The study had a placebo group and three groups receiving different doses of sildenafil (20mg, 40mg, and 80mg) taken three times daily. The changes in meters are likely referring to some kind of physical measurement or activity being tracked. No further details about the study or what the measurement represents are provided.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

This appears to be a table containing data related to a study on the effects of Sildenafil on individuals with Idiopathic Pulmonary Arterial Hypertension. The table shows baseline walk distance, age, gender, and mean pulmonary artery pressure among other variables, with corresponding numerical values. Additionally, there is a graph displaying placebo-corrected change in 6-minute walk distance.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.